WallStSmart

Merck & Company Inc (MRK)vsPrenetics Global Ltd (PRE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 71085% more annual revenue ($65.77B vs $92.39M). MRK leads profitability with a 13.6% profit margin vs -40.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

PRE

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -0.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

PRE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
248.6%10/10

Revenue surging 248.6% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PRE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$319.78M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-22.1%2/10

ROE of -22.1% — below average capital efficiency

Free Cash FlowQuality
$-22.02M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PRE

The strongest argument for PRE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 248.6% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : PRE

The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while PRE is a hypergrowth play — different risk/reward profiles.

PRE carries more volatility with a beta of 0.24 — expect wider price swings.

PRE is growing revenue faster at 248.6% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Prenetics Global Ltd

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Prenetics Global Ltd (PRE) is a leading health technology innovator specializing in advanced genetic and diagnostic testing solutions that empower both consumers and healthcare providers with essential health insights. The company has experienced robust international expansion, supported by strategic partnerships and a relentless focus on research and development. Positioned at the forefront of personalized medicine, Prenetics is well-equipped to meet the growing demand for accessible and actionable health information, making it a notable investment opportunity within the evolving healthcare sector.

Want to dig deeper into these stocks?